September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Anti-Angiogenic Polymer Therapeutic for Corneal Neovascularization
Author Affiliations & Notes
  • Crystal Shin
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Xiaoyong Yuan
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Daniela Marcano
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Lucas Isenhart
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Ken Simmons
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Stephen C Pflugfelder
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Ghanashyam Acharya
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Crystal Shin, None; Xiaoyong Yuan, None; Daniela Marcano, None; Lucas Isenhart, None; Ken Simmons, None; Stephen Pflugfelder, None; Ghanashyam Acharya, None
  • Footnotes
    Support  Department of Defense 1W81XWH-13-1-0146
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3516. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Crystal Shin, Xiaoyong Yuan, Daniela Marcano, Lucas Isenhart, Ken Simmons, Stephen C Pflugfelder, Ghanashyam Acharya; Anti-Angiogenic Polymer Therapeutic for Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3516.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently corneal neovascularization is treated with topical formulations of anti-inflammatory or anti-VEGF drugs which can cause adverse side effects. The purpose of this study was to develop a non-invasive biopolymer therapeutic nanowafer to treat corneal neovascularization. The in vivo efficacy of the nanowafer was evaluated in a murine ocular burn model.

Methods : A sulfated polysaccharide, dextran sulfate (DS) nanowafers and an antiangiogenic drug, axitinib, loaded DS nanowafers were fabricated by hydrogel template strategy. The chemical burn induced mouse corneas were treated daily with the DS nanowafers, axitinib loaded DS (Axi-DS) nanowafers, DS eye drops to compare their therapeutic efficacies and to evaluate synergistic effect of DS. After treatments, mouse corneas were subjected to immunofluorescence imaging and RT-PCR analyses.

Results : Overall, the nanowafer treatment minimized corneal neovascularization when compared to untreated ocular burn corneas in murine models. Immunofluorescence images presented CD31 positive vasculature endothelium in corneas and showed the DS nanowafer treatment was as effective as Axi-DS nanowafer treatment in suppressing neovascularization. The RT-PCR analysis revealed that after five days of DS nanowafer treatment, gene expressions of proinflammatory cytokines (IL-1α and IL-1β) and angiogenic factors (VEGFA, VEGFR1, and VEGFR2) were downregulated (Figure 1). This result showed that DS nanowafer had anti-angiogenic effect on inhibiting corneal neovascularization.

Conclusions : This study demonstrated the anti-–angiogenic effect of a biopolymer, dextran sulfate, in a murine ocular burn model. In addition, an anti-angiogenic drug incorporated dextran sulfate nanowafer maximized their therapeutic efficacies.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Figure 1. RT-PCR analysis showing that downregulation of proinflammatory cytokines and angiogenic factors by nanowafer treatments

Figure 1. RT-PCR analysis showing that downregulation of proinflammatory cytokines and angiogenic factors by nanowafer treatments

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×